i. A person who is a contact of a probable or confirmed mpox case in the 21 days before the onset of signs or symptoms, and who presents with any of the following: acute onset of fever (>38.5°C), headache, myalgia (muscle pain/body aches), back pain, profound weakness or fatigue.
OR
ii. A per...son presenting since 01 January 2022 with an unexplained acute skin rash, mucosal lesions or lymphadenopathy (swollen lymph nodes). The skin rash may include single or multiple lesions in the ano-genital region or elsewhere on the body. Mucosal lesions may include single or multiple oral, conjunctival, urethral, penile, vaginal, or ano-rectal lesions. Ano-rectal lesions can also manifest as ano-rectal inflammation (proctitis), pain and/or bleeding.
AND
for which the following common causes of acute rash or skin lesions do not fully explain the clinical picture: varicella zoster, herpes zoster, measles, herpes simplex, bacterial skin infections, disseminated gonococcus infection, primary or secondary syphilis, chancroid, lymphogranuloma venereum, granuloma inguinale, molluscum contagiosum, allergic reaction (e.g., to plants); and any other locally relevant common causes of papular or vesicular rash.
more
mise à jour de la situation
Outbeak of Clade I MPXV in Subsaharan Africa
The tab is the result of a preliminary landscape of vaccines licensed or under development for Mpox
El Director General de la OMS, Dr. Tedros Adhanom Ghebreyesus, ha determinado que el recrudecimiento de la viruela símica (mpox) en la República Democrática del Congo y en un número creciente de países de África constituye una emergencia de salud pública de importancia internacional (ESPII) c...on arreglo al Reglamento Sanitario Internacional (2005) (RSI [2005]).
more
This document serves to provide interim guidance/ recommendations to carry out mpox surveillance activities mainly case investigation, contact tracing and isolation. For the development of this document WHO, UKHSA and CDC guidelines were referred to and adopted within the country context.
En esta nota técnica se explican los 20 aspectos que deben considerarse para evaluar el estado y la seguridad del equipo y los suministros de laboratorio. No se incluyen en este trabajo las instrucciones para los evaluadores de los puntos 93 (Estado y seguridad del equipo médico en las salas de op...eraciones y salas de recuperación) y 94 (Estado y seguridad del equipo de radiología e imagenología), que también forman parte del índice de seguridad hospitalaria.
more
La fièvre de Lassa est une fièvre hémorragique virale aiguë d'une durée d'une à quatre semaines qui sévit en Afrique occidentale. La fièvre de Lassa, une fièvre hémorragique virale avec des symptômes similaires à ceux de la maladie virale d'Ebola, est endémique dans une grande partie de... l'Afrique de l'Ouest et provoque généralement une poussée saisonnière de
Platform: OpenWHO
more
This toolkit is a comprehensive set of practical tools and resources designed to support country-level risk communication and community engagement (RCCE) practitioners, decision-makers, and partners to plan and implement readiness and response activities for yellow fever outbreaks. The toolkit conta...ins: information about yellow fever; RCCE considerations for how to approach key issues during yellow fever outbreaks; tools for understanding the context in which yellow fever outbreaks occur; methods for collecting data to inform strategy development and bring evidence into planning and implementation of activities; guidance to support vector control and immunization campaigns; and links to existing RCCE tools and training. It is one of a suite of toolkits on RCCE readiness and response to a range of disease and response areas.
more
This toolkit is a comprehensive set of practical tools and resources designed to support country-level risk communication and community engagement (RCCE) practitioners, decision-makers, and partners to plan and implement readiness and response activities for yellow fever outbreaks. The toolkit conta...ins: information about yellow fever; RCCE considerations for how to approach key issues during yellow fever outbreaks; tools for understanding the context in which yellow fever outbreaks occur; methods for collecting data to inform strategy development and bring evidence into planning and implementation of activities; guidance to support vector control and immunization campaigns; and links to existing RCCE tools and training. It is one of a suite of toolkits on RCCE readiness and response to a range of disease and response areas.
more
Hand hygiene is vital for safe health care delivery, yet practices at the point of care remain suboptimal worldwide. A comprehensive research agenda is therefore necessary to improve our understanding of factors influencing hand hygiene behaviour and to strengthen appropriate interventions. This age...nda will provide insightful ideas for researchers to focus their projects and funding proposals and will direct donors towards the areas of hand hygiene evidence that require urgent support and innovation. It will also guide decision-makers and stakeholders at the national and international level and support country efforts in updating and strengthening hand hygiene promotion programmes. Global collaboration and investment in hand hygiene research remain essential to promote safe and effective care worldwide.
more
DOWNLOAD (1.13 MB)
Many people with dengue can be cared for at home with adequate rest and hydration. But, if you experience any warning signs, go immediately to the nearest medical center.
Une flambée de maladie connue sous le nom de « variole du singe » sévit actuellement dans de nombreux pays où il n’y a généralement pas de cas. Cette situation peut être préoccupante, notamment pour les personnes dont les proches ou la communauté sont touchés. Certains cas ont été obs...ervés dans des centres de santé sexuelle parmi les homosexuels, les bisexuels et les autres hommes qui ont des rapports sexuels avec des hommes.
more
The Pandemic Influenza Pandemic (PIP) Framework's Partnership Contribution (PC) High-Level Implementation Plan III (HLIP III) outlines the strategy for strengthening global pandemic influenza preparedness from 2024 to 2030. HLIP III takes into consideration the lessons learned from the response to t...he COVID-19 pandemic, the gains made over time, including from previous HLIPs, and the broader programmatic and policy context in order to address gaps in pandemic influenza preparedness. Implementation of HLIP III will strengthen global, regional, and country-level pandemic influenza preparedness.
more
Las olas de transmisión de la fiebre amarilla ocurridas en la Región de las Américas entre el 2016 y el 2018 causaron el mayor número de casos humanos y epizoóticos registrados en varios decenios. La fiebre amarilla es una enfermedad hemorrágica viral grave que representa un desafío para el p...rofesional de salud: exige el reconocimiento temprano de signos y síntomas muchas veces inespecíficos, que pueden parecerse a otros síndromes febriles agudos. La detección temprana de los casos sospechosos o confirmados, el monitoreo de los signos vitales y las medidas de soporte vital, y el tratamiento de la insuficiencia hepática aguda siguen siendo las estrategias recomendadas para el manejo de los casos. El presente informe es el resultado de las deliberaciones sobre la experiencia de expertos de la Región en cuanto al manejo clínico de pacientes con fiebre amarilla, especialmente en brotes y epidemias, mediante la contextualización de esa experiencia en el conjunto actual de la evidencia médico-científica y la consideración de las directrices técnicas ya disponibles en los países de la Región. Presenta flujogramas para la evaluación inicial del paciente con sospecha clínica de fiebre amarilla y sugiere un conjunto mínimo de pruebas de laboratorio que puede ser útil cuando hay pocos recursos; además, detalla aspectos de la organización de los sistemas de salud para enfrentar brotes y epidemias de fiebre amarilla.
more
In the Region of the Americas, as of 24 February 2023 (16:00 EST), there are a total of 58,578 confirmed cases of mpox (Table 1, Figure 2) were reported from 31 countries and territories, including 76 deaths in: United States of America (34), Brazil (15), Peru (15), Mexico (4), Chile (2), Ecuador (3...), Argentina (2), and Cuba (1), reported from 31 (Table 1, Annex 1, Figure 3). In the last 4 weeks (28 January – 24 February 2023), 607 additional mpox cases were reported from 16 countries and territories, including 9 deaths in Ecuador (1) and United States (8). Eight countries in the Region account for 97% of confirmed cases: United States of America, Brazil, Colombia, Mexico, Peru, Canada, Chile, and Argentina – listed by total number of cases in decrease order (Figure 4). The number of new weekly reported cases in EW 7 compared to EW 6 of 2023 (% variation) decreased by 55%.
more